Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Date:2/24/2009

14,955 315,000 Capital lease obligations 20,347 21,632 Deferred revenue 55,567 61,349 Deferred gain 5,901 8,680 Other long-term liabilities 5,238 5,911 Total liabilities 370,382 510,664 Commitments and contingencies Stockholders' equity: Preferred stock - - Common stock 9 9 Capital in excess of par value 1,312,796 1,302,541 Accumulated other comprehensive income 1,439 1,643 Accumulated deficit (1,124,090) (1,089,754) Total stockholders' equity 190,154 214,439 Total liabilities and stockholders' equity $560,536 $725,103 (1) The consolidated balance sheet at December 31, 2007 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. Certain 2007 amounts have been reclassified between line items to conform with the 2008 presentation. NEKTAR THERAPEUTICS CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (unaudited) Twelve-Months Ended December 31, 2008 2007 Cash flows provided by (used in) operating activities: Net loss $(34,336)
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Nektar to Announce Year-End 2008 Financial Results on Wednesday, February 25, 2009 After Close of U.S.-Based Financial Markets
2. Nektar Announces Retirement of Irwin Lerner from Board of Directors
3. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Nektar Therapeutics to Webcast R&D Day on November 12th
6. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
7. Nektar Therapeutics President and CEO Howard W. Robin to Present at Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City
8. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at UBS 2008 Global Life Sciences Conference in New York City
9. Nektar to Announce Financial Results for the Second Quarter of 2008 on Wednesday, August 6, 2008, After Close of U.S.-Based Financial Markets
10. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
11. Nektars PEGylation Technology Enables Peptide Mimetic, Highlighted by Data Presented at 45th ERA-EDTA Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... - Oncothyreon Inc. (NASDAQ: ONTY ) today ... of its Common Stock and Series A Convertible Preferred ... Series A Convertible Preferred Stock is non-voting and convertible ... will be prohibited if, as a result, the holder ... of the Common Stock then outstanding. As part of ...
(Date:9/17/2014)... 17, 2014 A biodegradable polymer ... such as bacteria, fungi, and algae into smaller ... biomass, inorganic compounds, carbon dioxide, and humus in ... base and improved costs, biodegradable polymers are proving ... alternative to conventional polymers. Primary factors that are ...
(Date:9/17/2014)... Intarcia Therapeutics, Inc. today announced the presentation ... cost and predictability of non-adherence in type 2 diabetes ... the European Association for the Study of Diabetes (EASD). ... Ph.D., of Analysis Group, Inc. presented data from the ... to characterize the prevalence of non-adherence and serial non-adherence, ...
(Date:9/17/2014)... Mass. , Sept. 17, 2014 ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced that it has been ... and Trademark Office on its unique delivery system ... ) to phagocytic cells for the treatment of ...
Breaking Biology Technology:Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4
... 15, 2011 Generex Biotechnology Corporation ( www.generex.com ... the status of the previously announced spinout of ... ). The Company is in the ... several transaction opportunities, including both shell companies and ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) announced ... provide an overview of the company,s business strategy at ... the UBS 2011 Global Life Sciences Conference which will ... addition, Geoffrey Nichol, M.B., Ch.B., Sangamo,s executive vice president ...
... Aperion Biologics, Inc. announced that it has reached ... Company,s clinical trial of its Z-Lig™ Anterior Cruciate Ligament ... of the knee. The randomized multicenter study commenced in ... provide safety and performance data in the reconstruction of ...
Cached Biology Technology:Generex Provides Update on Spinout of Antigen Express 2Generex Provides Update on Spinout of Antigen Express 3Generex Provides Update on Spinout of Antigen Express 4Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference 2Aperion Biologics Reaches Midpoint of Enrollment in Z-Lig™ Anterior Cruciate Ligament Reconstruction Medical Device Performance Trial 2
(Date:9/16/2014)... Menopause Society (NAMS) has published its key, evidence-based ... everything from hot flashes to heart disease. The ... for Clinical Care of Midlife Women," was published ... . This is the first, comprehensive set of ... freely available to all clinicians who care for ...
(Date:9/16/2014)... Two Johns Hopkins neuroscientists have discovered the "molecular brakes" ... inner ear cochleas of mice. These "hair cells" translate ... the brain and are interpreted as sounds. If the ... , A summary of the research will be ... Sept. 16. , "The proteins Hey1 and Hey2 act ...
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3
... world,s top biodiversity hotspot for reptiles and amphibians, according ... from the University of California, Berkeley, Southern Illinois University ... The park, which encompasses lowland Amazonian rain forest, high-altitude ... well known for its huge variety of bird life, ...
... to climate change are being compiled by research groups ... various sources results in different climate projections; hence, the ... arrive at a consensus regarding future climate estimates. ... SIAM Journal on Uncertainty Quantification , authors Matthew ...
... , New Rochelle, NY, February 19, 2014Joseph C. Glorioso, ... devoted much of his research career to developing herpes ... cells. In recognition of his leadership and accomplishments, ... Gene Therapy , a peer-reviewed journal from Mary Ann ...
Cached Biology News:Peru's Manu National Park sets new biodiversity record 2Peru's Manu National Park sets new biodiversity record 3Statistics research could build consensus around climate predictions 2Statistics research could build consensus around climate predictions 3Statistics research could build consensus around climate predictions 4Joseph Glorioso, Ph.D., receives Pioneer Award 2